Literature DB >> 20479360

APOE epsilon4 and the cognitive genetics of multiple sclerosis.

O Ghaffar1, M Reis, N Pennell, P O'Connor, A Feinstein.   

Abstract

BACKGROUND: Evidence linking APOE to myelin repair, neuronal plasticity, and cerebral inflammatory processes suggests that it may be relevant in multiple sclerosis (MS). The purpose of this study was to determine whether the epsilon4 allele of APOE is associated with cognitive deficits in patients with MS.
METHOD: Using a case-control design, 50 patients with MS with the epsilon4 allele (epsilon4+) and 50 epsilon4-negative (epsilon4-) patients with MS were tested using a comprehensive battery of tests evaluating the cognitive domains most often affected in MS.
RESULTS: The epsilon4+ and epsilon4- patients with MS were well-matched with respect to demographic variables (age, gender, ethnicity, education, employment status, premorbid IQ) and disease variables (disease course, disease duration, Expanded Disability Status Scale, 25-foot timed walk, 9-hole pegboard test). In addition, the groups were similar in depressive symptoms, in the proportion of patients receiving disease-modifying therapy, and in carriage of the APOE epsilon2 allele. Results showed that none of the 11 cognitive outcome variables differed between epsilon4+ and epsilon4- patients with MS. Cognitive measures were also unrelated to epsilon4 interactions with age and gender. The incidence of overall cognitive dysfunction did not differ between epsilon4+ and epsilon4- groups, nor did failure on any test, and epsilon4 carriage was not a significant predictor of any adverse cognitive outcome. These negative results endured with the exclusion of epsilon2+ subjects from the analyses.
CONCLUSION: This study does not support a role for the epsilon4 allele in cognitive dysfunction in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20479360      PMCID: PMC2875133          DOI: 10.1212/WNL.0b013e3181e074a7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

Review 1.  Genetic variation in memory functioning.

Authors:  Lars-Göran Nilsson; Lars Nyberg; Lars Bäckman
Journal:  Neurosci Biobehav Rev       Date:  2002-11       Impact factor: 8.989

2.  Development and validation of a model for estimating premorbid verbal intelligence in the elderly.

Authors:  E Grober; M Sliwinski
Journal:  J Clin Exp Neuropsychol       Date:  1991-11       Impact factor: 2.475

3.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Authors:  G R Cutter; M L Baier; R A Rudick; D L Cookfair; J S Fischer; J Petkau; K Syndulko; B G Weinshenker; J P Antel; C Confavreux; G W Ellison; F Lublin; A E Miller; S M Rao; S Reingold; A Thompson; E Willoughby
Journal:  Brain       Date:  1999-05       Impact factor: 13.501

4.  Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis.

Authors:  Giovanni Savettieri; Demetrio Messina; Virginia Andreoli; Simona Bonavita; Carlo Caltagirone; Rita Cittadella; Deborah Farina; Maria Carolina Fazio; Paolo Girlanda; Francesco Le Pira; Maria Liguori; Alessandra Lugaresi; Ugo Nocentini; Arturo Reggio; Giuseppe Salemi; Gioacchino Tedeschi; Maria Trojano; Paola Valentino; Aldo Quattrone
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

5.  Apolipoprotein E and cognitive performance: a meta-analysis.

Authors:  Brent J Small; Christopher B Rosnick; Laura Fratiglioni; Lars Bäckman
Journal:  Psychol Aging       Date:  2004-12

6.  Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.

Authors:  S M Rao; G J Leo; L Bernardin; F Unverzagt
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

7.  The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery.

Authors:  G A Carlesimo; C Caltagirone; G Gainotti
Journal:  Eur Neurol       Date:  1996       Impact factor: 1.710

8.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.

Authors:  E H Corder; A M Saunders; N J Risch; W J Strittmatter; D E Schmechel; P C Gaskell; J B Rimmler; P A Locke; P M Conneally; K E Schmader
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

9.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

10.  Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning.

Authors:  S M Rao; G J Leo; L Ellington; T Nauertz; L Bernardin; F Unverzagt
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

View more
  5 in total

Review 1.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

Review 2.  Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.

Authors:  Manuel Comabella; Koen Vandenbroeck
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

Review 3.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 4.  Risk factors for and management of cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  Nat Rev Neurol       Date:  2011-05-10       Impact factor: 42.937

5.  The role of apolipoprotein E as a risk factor for an earlier age at onset for Machado-Joseph disease is doubtful.

Authors:  Qi Zhou; Wang Ni; Yi Dong; Ning Wang; Shi-Rui Gan; Zhi-Ying Wu
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.